Product Description
SHR3680 is a novel and pure androgen-receptor (AR) antagonist that shows a potent antitumor activity against CRPC but with much less brain distribution than enzalutamide in preclinical study.
Mechanisms of Action: AR Antagonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Jiangsu Hengrui Medicine Co
Company Location: Asia Pacific
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Bulgaria, China, Czech Republic, Poland
Active Clinical Trial Count: 11
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Prostate Cancer
Phase 2: Ductal Carcinoma
Phase 1: Hepatic Insufficiency
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
2024-515194-10-00 |
SHR-3680-III-HSPC | P3 |
Not yet recruiting |
Prostate Cancer |
2025-12-31 |
2025-05-02 |
Treatments |
|
NCT06348264 |
SDC-1 | P2 |
Recruiting |
Ductal Carcinoma |
2029-03-30 |
2% |
2024-04-05 |
Primary Endpoints|Treatments |
CTR20180680 |
CTR20180680 | P1 |
Active, not recruiting |
Prostate Cancer |
None |
2025-04-29 |
Patient Enrollment|Treatments |
|
CTR20202364 |
CTR20202364 | P1 |
Active, not recruiting |
Prostate Cancer |
None |
2025-04-29 |
Patient Enrollment|Start Date|Treatments|Trial Status |
|
NCT05753566 |
IUNU-PC-119 | P2 |
Recruiting |
Prostate Cancer |
2027-03-01 |
36% |
2023-03-07 |
Primary Endpoints|Treatments|Trial Status |
CTR20202072 |
CTR20202072 | P2 |
Active, not recruiting |
Prostate Cancer |
None |
2025-04-29 |
Patient Enrollment|Treatments|Trial Status |
|
NCT05009290 |
SHR3680-III-302 | P3 |
Recruiting |
Prostate Cancer |
2027-10-30 |
32% |
2022-01-14 |
Primary Endpoints|Start Date|Treatments|Trial Status |
NCT07241416 |
MA-PCa-III-021 | P3 |
Recruiting |
Prostate Cancer |
2027-03-01 |
19% |
2025-12-25 |
Primary Endpoints|Start Date|Treatments|Trial Status |
CTR20222638 |
CTR20222638 | P1 |
Recruiting |
Prostate Cancer |
None |
2025-04-29 |
Patient Enrollment|Treatments |
|
CTR20180560 |
CTR20180560 | P3 |
Active, not recruiting |
Prostate Cancer |
None |
2025-04-29 |
Patient Enrollment|Treatments |
|
CTR20202327 |
CTR20202327 | P1 |
Recruiting |
Hepatic Insufficiency |
None |
2025-04-29 |
Patient Enrollment|Start Date|Treatments|Trial Status |